



Rheumatology

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report Rheumatology Q1 2011

Therapeutic Class:	Autoimmune Disorders
Focus Area:	Rheumatoid Arthritis
Specialty/Location:	Rheumatologists/N. America, Europe
Number of Interviews:	6
Number of Pages:	160
Publication Date:	April 2011
Principal Authors:	Kim Grant Tricia L. Hanlon Jeffrey D. Berk, Ph.D., MBA
Product Code:	MAIRQ111-32
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract: Rheumatology Thought Leader Panel #32 is based on 6 interviews conducted with American and European rheumatology thought leaders in Feb-Apr 2011. The Panel focused extensively on positioning, strengths and weaknesses, and expected pricing for tofacitinib and fostamatinib. Other topics covered:

- Any advantages expected in the next generation anti-IL-6 approaches?
- Interest in IL-17 or IL-23 inhibition for RA?
- At the request of some of our long-term clients we've polled our Panel on chemokine receptor antagonists. This is going to be a very challenging approach, mainly due to redundancy, but we'll let the Panel speak for itself.

Full transcripts of six qualitative interviews with rheumatologists are included with this report.

Drugs/Companies Discussed:

Company	Drug	Brand
Abbott	adalimumab	Humira
Alder / BMS	BMS-945429 / ALD-518	
Amgen	AMG-827	
Amgen / Wyeth / Pfizer	etanercept	Enbrel
AstraZeneca	AZD5672	
Bristol-Myers Squibb	BMS-582949 CCR1	
Caprecom	etanercept biosimilar	Etanar
Celgene	CC-930	
Centocor / Schering-Plough (Merck)	golimumab ustekinumab	Simponi Stelara
Ferring / Conaris	FE301	
Galapagos	GLPG0634	
Genentech / Roche Genentech / Roche / Chugai Covagen / Roche Genentech	rontalizumab (rhuMAb IFN alpha) tocilizumab Fynomers	Actemra / RoActemra
GSK / ChemoCentryx	CCX-354	
Lilly	LY-2439821	
Incyte / Lilly	INCB-28050	
MedImmune	sifalimumab	
Merck	SCH-900222 anti-IL-17	
Mycenax Biotech	etanercept	TuNEX
Novartis	secukinumab; AIN-457	
Pfizer	tofacitinib; tasocitinib; CP-690550 etanercept CP-481,715	Enbrel
Rigel / AstraZeneca	fostamatinib (R788)	
Sanofi-Aventis / Regeneron	SAR153191 / REGN-88 leflunomide	Arava
Takeda / Millennium	MLN-3897	
UCB	certolizumab CDP-6038	Cimzia
Vertex	VX-509	
YM Biosciences / Cytopia	CYT-387	

Table of Contents

EXECUTIVE SUMMARY 4

Report Highlights6

KEY FINDINGS 15

CCR (chemokine receptor antagonists).....15

 CCR117

 CP-481,715 (Pfizer).....17

 MLN-3897 (Millennium)18

 CCX-354 (ChemoCentryx / GlaxoSmithKline)19

 BMS.....24

 CCR225

 CCR525

 Boehringer Ingelheim27

IP-10 / CXCL1027

Fynomers27

 Fynomers (Covagen / Roche)27

IL-6 / GP-130.....30

 Actemra (tocilizumab; Roche / Chugai).....31

 BMS-945429 / ALD-518 (Alder / BMS)36

 SAR153191 / REGN-88 (Sanofi-Aventis / Regeneron).....40

 CDP-6038 (UCB).....40

 FE301 (Ferring / Conaris).....42

IL-1742

 secukinumab (AIN-457; IL-17A; Novartis).....45

 LY2439821 (Lilly)48

 AMG-827 (Amgen)49

 DNAX / Schering-Plough Biopharma / Merck51

IL-2351

 Stelara (ustekinumab; Centocor)51

 SCH-900222 (Merck)52

Immunomodulator55

 Arava (leflunomide; Sanofi-Aventis).....55

Interferon alpha55

 rontalizumab (Genentech).....56

 sifalimumab (MedImmune).....58

JAK59

 tofacitinib (tasocitinib /CP-690550; Pfizer)59

 INCB28050 (Lilly / Incyte).....73

 VX-509 (Vertex).....75

 CYT-387 (Cytobia, YM Biosciences).....78

 CC-930 (Ligand / Celgene)78

GLPG0634 (Galapagos).....	78
p38	78
BMS-582949 (Ligand / Bristol-Myers Squibb).....	78
Syk	81
fostamatinib (Rigel / AstraZeneca).....	81
TNF	88
Cimzia (certolizumab; UCB)	92
Enbrel (etanercept; Amgen / Pfizer).....	93
Etanar (Caprecom), TuNEX (Mycenax Biotech); etanercept biosimilars.....	94
Simponi (golimumab; Centocor).....	96

THOUGHT LEADER INTERVIEWS 103

Interview BJE02546	103
Interview BJE02547	111
Interview BJE02548	118
Interview BJE02549	127
Interview BJE02550	140
Interview BJE02551	148